Clinical Trials Logo
  1. Home
  2. Malignant Glioma of Brain
  3. NCT06417281

Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid（5-ALA）

Malignant Glioma of Brain Clinical Trial

Official title:
A Phase III Clinical Trial of Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid

Clinical Trial Summary

This trial is an open-label, multicenter, phase III clinical study，conducted in patients with newly diagnosed or recurrent malignant high-grade (WHO grades 3~4) glioma, to evaluate the efficacy and safety of a single oral dose of 5-aminolevulinic acid (5-ALA) oral solution powder for fluorescence-guided tumor resection and photodynamic diagnosis.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06417281
Study type Interventional
Source Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Contact jingsong wu, doctor
Phone +8613701707118
Email wujinsong@huashan.org.cn
Status Not yet recruiting
Phase Phase 3
Start date June 2024
Completion date August 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03011671 - Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma Phase 1
Recruiting NCT05686798 - Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. Phase 1
Recruiting NCT02617134 - CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor Phase 1/Phase 2
Completed NCT03355794 - A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) Phase 1
Recruiting NCT04937244 - Pilot Study Evaluating the Optimization of the ORBEYE Blue Light Filter During Fluorescence-Guided Resection of Gliomas Phase 4
Recruiting NCT03423992 - Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas Phase 1
Not yet recruiting NCT04482933 - HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma Phase 2
Withdrawn NCT03176160 - LITT Palliative Treatment for Patients With Malignant Gliomas
Recruiting NCT02839954 - CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor Phase 1/Phase 2
Recruiting NCT03152318 - A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 Phase 1
Completed NCT00870181 - ADV-TK Improves Outcome of Recurrent High-Grade Glioma Phase 2
Completed NCT01550523 - Pilot Immunotherapy Trial for Recurrent Malignant Gliomas Phase 1
Terminated NCT01017653 - Panitumumab and Irinotecan for Malignant Gliomas Phase 2